Applicability of individualized metabolic surgery score for prediction of diabetes remission after endoscopic sleeve gastroplasty

Endoscopic sleeve gastroplasty (ESG) is a safe and effective obesity treatment. The individualized metabolic score (IMS) is a validated score that uses preoperative variables predicting T2D remission (DR) in bariatric surgery. We evaluated the applicability of using the IMS score to predict DR in patients after ESG. We performed a retrospective review of patients with obesity and T2D who underwent ESG. We calculated DR, IMS score, and severity, and divided patients based on IMS category. The cohort comprised 20 patients: 25% (5) mild, 55% (11) moderate, and 20% (4) severe IMS stages. DR was achieved in 60%, 45.5%, and 0% of patients with mild, moderate, and severe IMS scores ( = 0.08), respectively. IMS score was significantly associated with DR ( = 0.03), with the area under the curve of the receiver operating characteristic for predicting DR 0.85. These pilot data demonstrate that the IMS score appears to be useful in predicting DR after ESG.